Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Oculis Holding AGNASDAQ: OCS
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns positive
Q1 FY2026 Accumulated OCI was CHF 30.1M, compared with -CHF 1.96M a year earlier. Over 3 fiscal years it compounded at +134.1% a year.
Context
- Accumulated OCI amounted to 12.4% of total assets at the end of Q1 FY2026, up 11.4 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +1639.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
CHF · from the balance sheet
- Latest · FY2025
- 28.31M CHF
- Year-over-year change
- +1230.4%
- 4-year CAGR
- +156.3%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.31M | +1230.4% |
| FY2024 | 2024-12-31 | (2.5M) | -79.0% |
| FY2023 | 2023-12-31 | (1.4M) | -163.4% |
| FY2022 | 2022-12-31 | 2.21M | +236.4% |
| FY2021 | 2021-12-31 | 656K | — |
Accumulated OCI vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1639.0% is the highest of 3, against a peer median of -30.9%.
- Accumulated OCI amounts to 12.4% of total assets for OCS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 30.1M CHF | +1639.0% | +134.1% | 12.4% | |
| Mar 2026 | $802K USD | -13.1% | +6.9% | 0.3% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Sep 2025 | -$9.03M USD | -48.7% | — | 194.5% | |
| Peer median (excluding OCS) | — | -30.9% | +6.9% | 0.0% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 46.28M | 19.79M | 38.33M | 27.71M | 81.42M |
| Short-term Investments | 0 | 0 | 53.32M | 70.96M | 131.83M |
| Net Receivables | 0 | 0 | 7.95M | 777K | 994.13K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 911K | 1.08M | 0 | 0 | 4.89M |
| Total Current Assets | 47.98M | 23.66M | 101.02M | 104.9M | 219.14M |
| Property, Plant & Equipment (Net) | 1.29M | 1.12M | 1.04M | 1.69M | 3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 8.72M | 12.21M | 12.21M | 13.29M | 13.31M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 52K | 74K | 89K | 476K | 785.89K |
| Total Non-current Assets | 10.06M | 13.4M | 13.34M | 15.46M | 17.09M |
| Total Assets | 58.04M | 37.06M | 114.35M | 120.35M | 236.23M |
| Account Payables | 824K | 3.87M | 7.6M | 5.87M | 1.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 502.57K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 5.95M | 0 | 0 |
| Other Current Liabilities | 0 | 1 | (497K) | 19.85M | 34.48M |
| Total Current Liabilities | 4.06M | 12.02M | 19.09M | 44.24M | 36.79M |
| Long-term Debt | 113.5M | 122.45M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 857K | 91K | 1.11M | 1.87M | 1.34M |
| Total Non-current Liabilities | 114.94M | 123.03M | 1.54M | 2.74M | 3.15M |
| Total Liabilities | 119M | 135.05M | 20.63M | 46.97M | 39.94M |
| Common Stock | 335K | 39K | 366K | 446K | 587.67K |
| Retained Earnings | (72.28M) | (110.98M) | (199.78M) | (285.56M) | (384.95M) |
| Accumulated OCI | 656K | 2.21M | (1.4M) | (2.5M) | 28.31M |
| Other Stockholders Equity | 1 | 1 | 6.38M | 16.06M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (60.96M) | (97.99M) | 93.73M | 73.38M | 196.29M |
| Total Debt | 114.27M | 123.08M | 605K | 1.18M | 2.32M |
| Net Debt | 68M | 103.3M | (37.72M) | (26.53M) | (79.11M) |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.